Lenvatinib, sintilimab combined interventional treatment vs bevacizumab, sintilimab combined interventional treatment for intermediate-advanced unresectable hepatocellular carcinoma

doi:10.3748/wjg.v30.i43.4620

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 43

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (121)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-6) series, Tables (1-4) series.

Item

Count

PDF

HTML

Figures (1-6)

Tables (1-4)

Sum=55

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=57

Publishing Process of This Article

Item

Count

Browse

Download

Sum=1

Nov 21, 2024 (publication date) through Nov 1, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Nov 21, 2024; 30(43): 4620-4635
Published online Nov 21, 2024. doi: 10.3748/wjg.v30.i43.4620

Full Size Figure Download Figure

Figure 2 Kaplan-Meier curves between the lenvatinib plus sintilimab plus interventional treatment and bevacizumab plus sintilimab plus interventional treatment groups. A: Kaplan-Meier curves based on propensity score matching (PFS) before propensity score matching (PSM); B: Kaplan-Meier curves based on overall survival (OS) before PSM; C: Kaplan-Meier curves based on PFS after PSM; D: Kaplan-Meier curves based on OS after PSM. PFS: Progression-free survival; OS: Overall survival; PSM: Propensity score matching; BeSiIT: Bevacizumab plus sintilimab plus interventional treatment; LeSiIT: Lenvatinib plus sintilimab plus interventional treatment.

Citation: Han RY, Gan LJ, Lang MR, Ren SH, Liu DM, Li GT, Liu YY, Tian XD, Zhu KW, Sun LY, Chen L, Song TQ. Lenvatinib, sintilimab combined interventional treatment vs bevacizumab, sintilimab combined interventional treatment for intermediate-advanced unresectable hepatocellular carcinoma. World J Gastroenterol 2024; 30(43): 4620-4635
URL: https://www.wjgnet.com/1007-9327/full/v30/i43/4620.htm
DOI: https://dx.doi.org/10.3748/wjg.v30.i43.4620